Stock Prediction: Anticipating Fresenius's Major Dividend Announcement
Fresenius Medical Care's stock has not yet experienced a significant chart breakout following Q2 2025 results, as the price has shown a weak short-term trend. However, analysts predict a moderate rise of around 7% in the next three months, indicating a positive medium-term outlook.
In Q2 2025, Fresenius SE & Co. reported quarterly revenue of €6.48 billion, exceeding estimates of €5.83 billion, and raised earnings per share, suggesting improved operational performance. Although no explicit statement on raised full-year revenue guidance was found in the results, the positive momentum is a promising sign for the company's future.
The current price-to-earnings (P/E) ratios for Fresenius Medical Care are approximately:
- 2025 estimated P/E: around 14.5 to 19, depending on the calculation method. Morningstar shows a normalized P/E of 14.52, while some sources give a trailing P/E near 19.11.
- 2026 P/E ratio data is not explicitly detailed in the search results, but forward P/E is about 10.86 according to one source, implying an expectation of higher earnings in 2026 relative to the current price.
Analyst Veronika Dubajova described the coming year as "particularly exciting" for Fresenius. After Q2 results, Fresenius is targeting revenue growth of between five and seven percent. The price-to-earnings ratio for Fresenius is currently around 13 for 2025, and there is a possibility that it could drop to 12 next year.
Investors should keep a close eye on Fresenius Medical Care's stock as it navigates this exciting period. The stock has the potential to reach a new multi-year high in a friendly market environment. As always, it's essential to conduct thorough research and consider seeking advice from a financial advisor before making investment decisions.
References:
[1] Yahoo Finance. (2025). Fresenius Medical Care AG & Co. KGaA (FME). Retrieved August 16, 2025, from https://finance.yahoo.com/quote/FME?p=FME
[2] Morningstar. (2025). Fresenius Medical Care AG & Co. KGaA (FME). Retrieved August 16, 2025, from https://www.morningstar.co.uk/uk/stocks/xnas/fme/analysis
[3] Fresenius SE & Co. (2025). Fresenius SE & Co. KGaA: Q2 2025 Results. Retrieved August 16, 2025, from https://www.fresenius.com/en/investors/financial-reports-and-presentations/quarterly-reports/quarterly-reports-2025/q2-2025-results.html
[4] Reuters. (2025). Fresenius Medical Care's Q2 profit beats estimates, raises revenue guidance. Retrieved August 16, 2025, from https://www.reuters.com/business/healthcare-pharmaceuticals/fresenius-medical-cares-q2-profit-beats-estimates-raises-revenue-guidance-2025-08-04/
Fresenius Medical Care's Q2 2025 results show an improvement in operational performance, with raised earnings per share and revenue exceeding estimates. This positive momentum and the predictions of a 7% moderate rise in the next three months indicate a positive medium-term outlook for the company's business and investing prospects.
Analyst Veronika Dubajova considers the coming year to be "particularly exciting" for Fresenius, as the company targets revenue growth of between five and seven percent. Investors should monitor the company's stock, as it has the potential for a new multi-year high in a favorable market environment, and it may be beneficial to conduct thorough finance research and seek advice from a financial advisor before making investment decisions.
